[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353218-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353218-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","igfbp-in-tumor-immunity-a-novel-target-for-cancer-immunotherapy","IGFBP in tumor immunity - a novel target for cancer immunotherapy","","The insulin-like growth factor-binding protein (IGFBP) family comprises soluble bioactive molecules that, with insulin-like growth factors (IGFs) and their receptors, modulate endocrine, metabolic, and immune functions. IGFBPs act as signaling intermediaries driving migration, differentiation, proliferation, and apoptosis. Although immune regulation roles are established, translation to meaningful clinical progress remains limited, especially using human specimen-based research. This review synthesizes IGFBP mechanisms in tumor immunity and highlights therapeutic potential and clinical correlations with prognosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/igfbp-in-tumor-immunity-a-novel-target-for-cancer-immunotherapy/353218/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/igfbp-in-tumor-immunity-a-novel-target-for-cancer-immunotherapy/353218.png","ImageObject",300,407,{"name":42,"@type":43},"Blitz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are IGFBPs and why are they important in immune regulation?","Question",{"text":63,"@type":64},"IGFBPs are soluble bioactive molecules that, together with IGFs and their receptors, modulate immune functions. They act as signaling intermediaries that influence key cellular processes such as migration, differentiation, proliferation, and apoptosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does this review explain IGFBPs’ role in the tumor immune microenvironment?",{"text":68,"@type":64},"It examines how IGFBPs influence diverse tumor-resident cell populations, mainly through IGF-dependent and IGF-independent pathways. The review emphasizes their therapeutic potential for tumor immunology.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence connects IGFBP expression to patient outcomes?",{"text":72,"@type":64},"The review synthesizes recent clinical research data showing correlations between IGFBP expression levels and patient prognosis across multiple cancer types. This supports their translational potential as immunotherapy targets.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353218,1790816897,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Lei et al. Journal of Translational Medicine (2026) 24:833  \n[https://doi.org/10.1186/s12967-026-08204-z](https://doi.org/10.1186/s12967-026-08204-z)  \nJournal of Translational Medicine  \nREVIEW Open Access  \nIGFBP in tumor immunity: a novel target for cancer immunotherapy  \nQingqiang Lei 1†, Liangbin Lin2,3,4† and Hui Yu5*  \nAbstract  \nBackground The insulin-like growth factor-binding protein (IGFBP) family consists of soluble bioactive molecules that, together with insulin-like growth factors (IGFs) and their receptors, are critical modulators of endocrine, metabolic, and immune functions. IGFBPs serve as signaling intermediaries in fundamental cellular processes such as migration, differentiation, proliferation, and apoptosis. Although their role in immune regulation is well-documented, this understanding has not yet led to significant clinical progress, particularly in research utilizing human specimens. Main body This review synthesizes current knowledge on the functions and mechanisms of IGFBPs within immune regulation and tumor immunology, highlighting their therapeutic potential. We specifically examine how IGFBPs influence diverse cell populations residing in the tumor immune microenvironment, primarily through IGFdependent and IGF-independent pathways. The article highlights future research directions and potential targets for novel immunotherapy strategies. This article also synthesizes the latest clinical research data on the correlation between IGFBP expression levels and patient prognosis across various cancer types, strengthening the translational potential of IGFBPs as targets for immunotherapy.  \nConclusion By detailing the impact of IGFBPs on the tumor immune landscape, we position this protein family as promising targets for the development of novel cancer immunotherapies.  \nKeywords Insulin-like growth factor-binding protein (IGFBP), Immune system, Tumor immunity, Cancer Immunotherapy  \n†Qingqiang Lei and Liangbin Lin equally contributed to this work.  \n*Correspondence: Hui Yu[yuhui@swjtu.edu.cn](yuhui@swjtu.edu.cn)  \n1Center of Bone Metabolism and Repair, Department of Wound Repair and Rehabilitation Medicine, State Key Laboratory of Trauma, Burns and Combined Injury, Trauma Center, Research Institute of Surgery, Daping Hospital, Army Medical University, Chongqing 400000, China 2Medical Research Center, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610014, China  \n3Obesity and Metabolism Medicine-Engineering Integration Laboratory, Department of General Surgery, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University,  \nChengdu 610031, China  \n4The Center of Gastrointestinal and Minimally Invasive Surgery, Department of General Surgery, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University,  \nChengdu 610031, China  \n5Department of Urology, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu 610014, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](","cbCaim99CpaWzSvX","https://ap.wps.com/l/cbCaim99CpaWzSvX","pdf",2233222,21,"English","# Abstract\n# Introduction\n## Innate and adaptive immune systems\n## Roles of IGFs, IGF receptors, and IGFBPs in immune regulation\n# Main body\n## IGFBP functions in immune regulation and tumor immunology\n## IGF-dependent and IGF-independent pathways\n## Translational evidence linking IGFBP expression to prognosis\n# Conclusion","[{\"question\":\"What are IGFBPs and why are they important in immune regulation?\",\"answer\":\"IGFBPs are soluble bioactive molecules that, together with IGFs and their receptors, modulate immune functions. They act as signaling intermediaries that influence key cellular processes such as migration, differentiation, proliferation, and apoptosis.\"},{\"question\":\"How does this review explain IGFBPs’ role in the tumor immune microenvironment?\",\"answer\":\"It examines how IGFBPs influence diverse tumor-resident cell populations, mainly through IGF-dependent and IGF-independent pathways. The review emphasizes their therapeutic potential for tumor immunology.\"},{\"question\":\"What evidence connects IGFBP expression to patient outcomes?\",\"answer\":\"The review synthesizes recent clinical research data showing correlations between IGFBP expression levels and patient prognosis across multiple cancer types. This supports their translational potential as immunotherapy targets.\"}]","IGFBP in tumor immunity - a novel target for cancer immunotherapy | PDF",1790103622,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e954c249c4d4b19238f6e9fa5c12e955.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a95265e51eadce1b9c731c56e3f1451.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08848cfc9e520207cb71fca010784c52.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0a9fa0ac53eb78ce3654b397d5df665.webp",980,1306]